Measurement of Choroidal Neovascular Area in Age-Related Macular Degeneration using Modified Otsu’s Thresholding Method
Authors
Abstract:
Introduction: Age-related Macular Degeneration (AMD) is one of the most important causes of irreversible blindness in the developed world and prevents the affected person from performing simple tasks such as reading, driving and facial recognition. In the AMD, new blood vessels grow underneath the retina in a process called choroidal neovascularisation (CNV). There is much interest in the quantification of the angiographic features of CNV, as these parameters are used as markers for monitoring the response to CNV treatment. To date, the techniques used in angiographic analysis are based on subjective interpretation by experienced clinicians. The goal of the present study was to propose an automatic algorithm for determining the extent of CNV. Materials and Methods: The proposed algorithm was used to analyze indocyanine angiograms of 12 patients with CNV. The angiograms were acquired by a confocal scanning laser ophthalmoscope. The algorithm included an adaptive Wiener filtering technique, a top-hat morphology method and a new thresholding technique based on a modification of Otsu’s method. The area of each lesion was obtained and compared with a subjective evaluation of CNV. Finally, each area was expressed in square millimeters by making a cylindrical tube filled with indocyanine green. Results: The CNV area was determined by the proposed algorithm and an observer. No significant differences were observed between the two data sets (p>0.05). Discussion and conclusion: This study demonstrates that the proposed algorithm based on a modification of Otsu’s method can be used to measure the area of CNV.
similar resources
Choroidal perfusion perturbations in non-neovascular age related macular degeneration.
AIM Choroidal perfusion, affected in age related macular degeneration (AMD), is difficult to objectively assess given the overlying retinal circulation. This study more objectively compared choroidal perfusion parameters in a group with non-neovascular AMD to an unaffected age matched control group. METHODS 21 non-neovascular AMD subjects and 21 age matched control subjects without evidence o...
full textTranspupilary thermotherapy of occult subfoveal choroidal neovascularization secondary to age related macular degeneration
Abstract Background: Transpupillary thermotherapy is a new treatment for subfoveal choroidal neovascularization which needs further evaluation. This study was aimed to evaluate the efficacy of transpupillary thermotherapy on regression of occult subfoveal choroidal neovascularization with or without pigment epithelial detachment in patients with age-related macular degeneration. Methods: In a ...
full textRanibizumab in neovascular age-related macular degeneration
BACKGROUND Ranibizumab--a recombinant, humanized, monoclonal antibody Fab that neutralizes all active forms of vascular endothelial growth factor A--has been evaluated for the treatment of neovascular age-related macular degeneration. METHODS In this multicenter, 2-year, double-blind, sham-controlled study, we randomly assigned patients with age-related macular degeneration with either minima...
full textTreatment of Neovascular Age Related Macular Degeneration
Until the end of the last century, no intervention could alter the natural history of the disease. Only in the last few decades, the retina specialists began to intervene in order to minimize the visual loss in those patients. Last ten years have been especially exciting as the new treatment modalities emerged and for the first time we could not only halt the progression of the deterioration, b...
full textPegaptanib for neovascular age-related macular degeneration.
(1) Neovascular (wet) age-related macular degeneration (AMD) results from the growth of abnormal blood vessels under the retina (choroidal neovascularization). Sudden and permanent vision loss occurs as these vessels grow, leak, bleed, and scar. (2) A human protein, vascular endothelial growth factor (VEGF), is implicated in the development of wet AMD. Pegaptanib attaches to VEGF and blocks its...
full textMy Resources
Journal title
volume 5 issue Issue 3,4
pages 77- 84
publication date 2008-12-01
By following a journal you will be notified via email when a new issue of this journal is published.
Hosted on Doprax cloud platform doprax.com
copyright © 2015-2023